中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (6): 464-469.doi: 10.12144/zgmfskin202606464

• 综述 • 上一篇    下一篇

甲银屑病的系统药物治疗进展

严夏梅1*,乔朱卉2,3*,史茗岚4,崔雅倩5,曾丽华3,侯素春4   

  1. 1深圳市南山区妇幼保健院皮肤科，广东深圳，518067；2北京中医药大学深圳医院（龙岗）皮肤科，广东深圳，518172；3香港大学深圳医院皮肤科，广东深圳，518053；4深圳大学总医院皮肤科，广东深圳，518055；5深圳市龙华区人民医院皮肤科，广东深圳，518109 *共同第一作者
  • 出版日期:2026-06-15 发布日期:2026-06-04

Update of systemic pharmacotherapy for nail psoriasis

YAN Xiamei1*, QIAO Zhuhui2,3*, SHI Minglan4, CUI Yaqian5, ZENG Lihua3, HOU Suchun4   

  1. 1 Department of Dermatology, Nanshan Maternity and Child Health Care Hospital, Shenzhen 518067, China; 2 Department of Dermatology, Shenzhen Hospital, Beijing University of Chinese Medicine (Longgang), Shenzhen 518172, China; 3 Department of Dermatology, Shenzhen Hospital, The University of Hong Kong, Shenzhen 518053, China; 4 Department of Dermatology, Shenzhen University General Hospital, Shenzhen 518055, China; 5 Department of Dermatology, Shenzhen Longhua People's Hospital, Shenzhen 518109, China *Co-first authors
  • Online:2026-06-15 Published:2026-06-04

PDF (PC)

3

摘要： 甲银屑病（nail psoriasis，NP）是银屑病累及甲床或甲母质引发的甲病变。NP与关节损害、生活质量降低及心血管风险升高显著相关，治疗难度大。本文对NP系统药物治疗进展（传统药物、生物制剂、小分子靶向药）进行综述，重点分析疗效与安全性证据，并展望个体化治疗趋势。

关键词: 甲银屑病, 系统治疗, 生物制剂, 小分子药物

Abstract: Nail psoriasis (NP) is a nail disorder caused by psoriasis involving the nail bed and nail matrix. NP is significantly associated with joint damage, reduced quality of life, and an increased risk of cardiovascular events, posing substantial therapeutic challenges. This paper reviews recent advances in the systemic pharmacotherapy of NP—including conventional agents, biologics, and small-molecule targeted drugs，focuses on the evidence of efficacy and safety， and prospects the trend of personalized therapy.

Key words: nail psoriasis, systemic therapy, biologics, small-molecule drugs